Jonathan Kay on #RNL2023:
Biosimilar is well-researched with cost savings
These savings should benefit the patients
Incentives for physicians as well in form of decreased prior auth burdens
@RheumNow
Links:
18-03-2023
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.